|
Molecular properties generated using the CDK |
Classification ![]() |
|
Compound class | Synthetic organic |
IUPAC Name ![]() |
6-[2-[[4-amino-3-(3-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-[(2-chlorophenyl)methyl]-4-oxoquinazolin-5-yl]-N,N-bis(2-methoxyethyl)hex-5-ynamide |
Synonyms ![]() |
RV-1729 |
Comments |
RV1729 is a clinical stage PI3Kγδ inhibitor that is being developed by Janssen Biotech subsidiary RespiVert (and licensed to Pulmatrix in 2017). The chemical structure is claimed in patent WO/2012/052753 [1-2]. |
Database Links ![]() |
|
BindingDB Ligand | 200639 |
CAS Registry No. | 1293915-42-0 (source: PubChem) |
ChEMBL Ligand | CHEMBL3919512 |
GtoPdb PubChem SID | 381118872 |
PubChem CID | 52913198 |
Search Google for chemical match using the InChIKey | UBLOHCIYTDRGJH-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | UBLOHCIYTDRGJH |
Search UniChem for chemical match using the InChIKey | UBLOHCIYTDRGJH-UHFFFAOYSA-N |
Search UniChem for chemicals with the same backbone | UBLOHCIYTDRGJH |